GLUE
Price
$6.22
Change
-$0.41 (-6.18%)
Updated
Feb 21 closing price
Capitalization
382.14M
19 days until earnings call
NVAX
Price
$7.99
Change
+$0.07 (+0.88%)
Updated
Feb 21 closing price
Capitalization
1.28B
10 days until earnings call
Ad is loading...

GLUE vs NVAX

Header iconGLUE vs NVAX Comparison
Open Charts GLUE vs NVAXBanner chart's image
Monte Rosa Therapeutics
Price$6.22
Change-$0.41 (-6.18%)
Volume$531.05K
Capitalization382.14M
Novavax
Price$7.99
Change+$0.07 (+0.88%)
Volume$10.67M
Capitalization1.28B
GLUE vs NVAX Comparison Chart
Loading...
GLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GLUE vs. NVAX commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GLUE is a Hold and NVAX is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (GLUE: $6.55 vs. NVAX: $8.25)
Brand notoriety: GLUE: Not notable vs. NVAX: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GLUE: 44% vs. NVAX: 92%
Market capitalization -- GLUE: $382.14M vs. NVAX: $1.28B
GLUE [@Biotechnology] is valued at $382.14M. NVAX’s [@Biotechnology] market capitalization is $1.28B. The market cap for tickers in the [@Biotechnology] industry ranges from $393.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GLUE’s FA Score shows that 0 FA rating(s) are green whileNVAX’s FA Score has 0 green FA rating(s).

  • GLUE’s FA Score: 0 green, 5 red.
  • NVAX’s FA Score: 0 green, 5 red.
According to our system of comparison, GLUE is a better buy in the long-term than NVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GLUE’s TA Score shows that 3 TA indicator(s) are bullish while NVAX’s TA Score has 2 bullish TA indicator(s).

  • GLUE’s TA Score: 3 bullish, 4 bearish.
  • NVAX’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, GLUE is a better buy in the short-term than NVAX.

Price Growth

GLUE (@Biotechnology) experienced а +7.20% price change this week, while NVAX (@Biotechnology) price change was +2.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.27%. For the same industry, the average monthly price growth was +3.99%, and the average quarterly price growth was +2.35%.

Reported Earning Dates

GLUE is expected to report earnings on May 08, 2025.

NVAX is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (+4.27% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVAX($1.28B) has a higher market cap than GLUE($382M). NVAX YTD gains are higher at: 2.612 vs. GLUE (-5.620). GLUE has higher annual earnings (EBITDA): -121.07M vs. NVAX (-216.36M). NVAX has more cash in the bank: 910M vs. GLUE (242M). GLUE has less debt than NVAX: GLUE (43.7M) vs NVAX (233M). NVAX has higher revenues than GLUE: NVAX (847M) vs GLUE (15M).
GLUENVAXGLUE / NVAX
Capitalization382M1.28B30%
EBITDA-121.07M-216.36M56%
Gain YTD-5.6202.612-215%
P/E RatioN/AN/A-
Revenue15M847M2%
Total Cash242M910M27%
Total Debt43.7M233M19%
FUNDAMENTALS RATINGS
NVAX: Fundamental Ratings
NVAX
OUTLOOK RATING
1..100
74
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
PROFIT vs RISK RATING
1..100
98
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
48
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
GLUENVAX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 5 days ago
90%
Bullish Trend 5 days ago
80%
Momentum
ODDS (%)
Bullish Trend 5 days ago
88%
Bearish Trend 5 days ago
87%
MACD
ODDS (%)
Bullish Trend 5 days ago
90%
Bearish Trend 5 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 5 days ago
87%
Bullish Trend 5 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
86%
Bearish Trend 5 days ago
87%
Advances
ODDS (%)
Bullish Trend 9 days ago
87%
Bullish Trend 5 days ago
85%
Declines
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 16 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
82%
View a ticker or compare two or three
Ad is loading...
GLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY611.491.79
+0.29%
SPDR® S&P 500® ETF Trust
AAPL244.47-0.13
-0.05%
Apple
GME26.97-0.03
-0.11%
GameStop Corp
BTC.X95539.550000-233.835940
-0.24%
Bitcoin cryptocurrency
TSLA354.11-1.73
-0.49%
Tesla

GLUE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLUE has been loosely correlated with RXRX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if GLUE jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLUE
1D Price
Change %
GLUE100%
-3.39%
RXRX - GLUE
44%
Loosely correlated
+1.04%
FATE - GLUE
42%
Loosely correlated
+7.75%
RCKT - GLUE
42%
Loosely correlated
+3.15%
CRBU - GLUE
41%
Loosely correlated
+5.19%
CRSP - GLUE
41%
Loosely correlated
+5.03%
More